Aleksander Krag
Aleksander Krag
Professor of Hepatology, Odense Universityhospital
Verified email at
Cited by
Cited by
Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension
BVIF de Franchis, Roberto
Journal of Hepatology 63 (3), 743-52, 2015
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
European Association for the Study of the Liver
Journal of hepatology 69 (2), 406-460, 2018
Spontaneous bacterial peritonitis: recent guidelines and beyond
R Wiest, A Krag, A Gerbes
Gut 61 (2), 297-310, 2012
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome
LL Gluud, K Christensen, E Christensen, A Krag
Hepatology 51 (2), 576-584, 2010
Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites
A Krag, F Bendtsen, JH Henriksen, S Møller
Gut 59 (01), 105-110, 2010
Terlipressin for hepatorenal syndrome
LL Gluud, K Christensen, E Christensen, A Krag
Cochrane Database of Systematic Reviews, 2012
Treatment of patients with cirrhosis
PS Ge, BA Runyon
New England Journal of Medicine 375 (8), 767-777, 2016
Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis
E Herrmann, V de Lédinghen, C Cassinotto, WCW Chu, VYF Leung, ...
Hepatology 67 (1), 260-272, 2018
The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease
A Krag, R Wiest, A Albillos, LL Gluud
Gut 61 (7), 967-969, 2012
Banding ligation versus beta‐blockers for primary prevention in oesophageal varices in adults
LL Gluud, A Krag
Cochrane Database of Systematic Reviews, 2012
Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome
A Krag, S Møller, JH Henriksen, NH Holstein‐Rathlou, FS Larsen, ...
Hepatology 46 (6), 1863-1871, 2007
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis
MA Karsdal, T Manon-Jensen, F Genovese, JH Kristensen, MJ Nielsen, ...
American Journal of Physiology-Gastrointestinal and Liver Physiology 308 (10 …, 2015
Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy
N Kimer, A Krag, S Møller, F Bendtsen, LL Gluud
Alimentary pharmacology & therapeutics 40 (2), 123-132, 2014
Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis
M Thiele, S Detlefsen, LS Møller, BS Madsen, JF Hansen, AD Fialla, ...
Gastroenterology 150 (1), 123-133, 2016
Treatment of acute variceal bleeding
F Bendtsen, A Krag, S Møller
Digestive and liver disease 40 (5), 328-336, 2008
Nonselective β‐blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients
L Bossen, A Krag, H Vilstrup, H Watson, P Jepsen
Hepatology 63 (6), 1968-1976, 2016
Meta‐analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices
M Thiele, A Krag, U Rohde, LL Gluud
Alimentary pharmacology & therapeutics 35 (10), 1155-1165, 2012
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta‐analysis
AD Fialla, M Israelsen, O Hamberg, A Krag, LL Gluud
Liver International 35 (9), 2072-2078, 2015
Meta‐analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia
E Dahl, LL Gluud, N Kimer, A Krag
Alimentary pharmacology & therapeutics 36 (7), 619-626, 2012
The system can't perform the operation now. Try again later.
Articles 1–20